SAN DIEGO, May 29 /PRNewswire-FirstCall/ -- As previously announced, the Vical Incorporated presentation at the Bank of America Health Care Conference on May 30 at 3:20 p.m. Pacific Time (6:20 p.m. Eastern Time) will be available by live and archived webcast through links on the events page at http://www.vical.com. The company’s presentations at the following series of upcoming conferences will not be webcast:
-- World Vaccine Congress Asia 2007 (Singapore, June 4 - 7). Vijay B. Samant, the company’s President and Chief Executive Officer will present a status report on recent developments in DNA vaccines for influenza in a pre-conference influenza vaccine summit chaired by Jacques-Francois Martin, President of Parteurop, France. Highlights will include the use of adjuvants such as the company’s patented Vaxfectin(TM) lipid-based compound, and a case study on the company’s pandemic influenza DNA vaccine program. -- Friedman Billings Ramsey Growth Conference (New York, May 30 - 31). -- The annual meeting of the American Society of Gene Therapy (Seattle, May 30 - June 3). -- The annual meeting of the American Society of Clinical Oncology (Chicago, June 1 - 5). -- Goldman Sachs Global Healthcare Conference (Dana Point, CA, June 12 - 15). -- Needham & Company Biotechnology & Medical Technology Conference (New York, June 13 - 14). -- Piper Jaffray London Health Care Conference .
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company’s focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company’s filings with the Securities and Exchange Commission. These forward-looking statements represent the company’s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Contacts: Investors: Media: Alan R. Engbring Susan Neath Vical Incorporated Porter Novelli Life Sciences (858) 646-1127 (619) 849-6007 Website: http://www.vical.com
Vical Incorporated
CONTACT: Investors, Alan R. Engbring of Vical Incorporated,+1-858-646-1127; or Media, Susan Neath of Porter Novelli Life Sciences,+1-619-849-6007
Web site: http://www.vical.com//
